Dr Lal Pathlabs Ltd (LALPATHLAB)
₹1,759.20
Mkt cap
₹29,491 Cr
P/E ratio
52.40
P/B
11.73
Div yield
0.80%
ROE
22.30%
ROCE
28.00%
EPS (TTM)
₹33.57
Book value
₹150
52W range
1,308–1,775
Sector
Healthcare
Dr. Lal PathLabs Limited is one of India’s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests and services for use in: core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. The services of DLPL are aimed at individual patients, hospitals and other healthcare providers and corporates. [1]
Health check
Constructive
ValuationFair
ProfitabilityStrong
GrowthModerate
TechnicalsBullish
52-week range
−0.89% from high₹1,759
₹1,308+34.54% from low₹1,775
Current
₹1,759.20
Prev close
₹1,775.00
Day
−0.89%
Price performance
1D
−0.89%
1W
+3.89%
1M
+4.14%
3M
+24.86%
6M
+27.74%
1Y
+17.98%
YTD
+19.33%
Financials
FRevenue, profit & margin
P/E ratio
52.4×
LALPATHLAB is 11% above the sector median of 47.4×
LALPATHLAB52.4×
Sector median47.4×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 541 | 601 | 539 | 545 | 602 | 660 | 597 | 603 | 670 | 731 | 660 | 703 | 798 | |
| Expenses | 395 | 424 | 398 | 401 | 432 | 458 | 443 | 434 | 478 | 506 | 480 | 516 | 550 | |
| Operating Profit | 146 | 178 | 141 | 145 | 170 | 202 | 154 | 169 | 192 | 224 | 179 | 187 | 248 | |
| OPM % | 27% | 30% | 26% | 27% | 28% | 31% | 26% | 28% | 29% | 31% | 27% | 27% | 31% | |
| Other Income | 14 | 18 | 18 | 18 | 21 | 22 | 25 | 26 | 28 | 25 | -6 | 24 | 32 | |
| Interest | 8 | 8 | 7 | 7 | 6 | 6 | 5 | 5 | 5 | 5 | 7 | 6 | 6 | |
| Depreciation | 35 | 36 | 36 | 37 | 35 | 35 | 36 | 36 | 35 | 40 | 42 | 45 | 44 | |
| Profit before tax | 118 | 152 | 116 | 120 | 150 | 183 | 138 | 153 | 181 | 204 | 124 | 160 | 229 | |
| Tax % | 29% | 27% | 29% | 28% | 28% | 29% | 29% | -1% | 26% | 25% | 26% | 17% | 25% | |
| Net Profit | 84 | 111 | 82 | 86 | 108 | 131 | 98 | 156 | 134 | 152 | 91 | 132 | 170 | |
| EPS in Rs | 4.95 | 6.55 | 4.87 | 5.06 | 6.37 | 7.73 | 5.78 | 9.26 | 7.90 | 8.99 | 5.40 | 7.84 | 10.11 | |
| Raw PDF |
Earnings
EResults dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move +0.31% · closed higher next day 19 of last 37
| Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 2 Nov '23◦ | 1 Feb '24◦ | 10 May '24◦ | 7 Aug '24◦ | 23 Oct '24◦ | 30 Jan '25◦ | 25 Apr '25◦ | 31 Jul '25 | 31 Oct '25 | 30 Jan '26 | 30 Apr '26 | 24 Jul '26 |
| Earnings day | +5.34% | −1.85% | +6.24% | −2.69% | −6.35% | −0.86% | −3.42% | +1.67% | +1.49% | +1.02% | −2.19% | +5.21% |
| +1 day | +7.46% | −3.13% | +6.12% | −1.92% | −3.63% | −0.57% | −4.58% | +2.52% | +5.36% | +1.61% | +12.56% | — |
| +5 days | +8.68% | −1.91% | +8.00% | +0.80% | −4.38% | −2.51% | −3.55% | +3.68% | 0.00% | +3.45% | +18.03% | — |
| +15 days | +7.49% | −2.06% | +13.90% | +4.36% | −8.84% | −8.77% | −3.09% | +8.90% | +1.03% | +0.51% | +16.62% | — |
| +30 days | +2.84% | −19.53% | +15.80% | +0.53% | −2.75% | −11.63% | +1.68% | +6.42% | −7.45% | −3.88% | +15.61% | — |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
CLast 6 months| Kind | Value | Ex-date | Record |
|---|---|---|---|
| dividend Dividend - Rs 4 Per Share | 4.00 | 25 Jun '26 | 26 Jun '26 |
| dividend Interim Dividend - Rs 3.50 Per Share | 3.50 | 5 Feb '26 | 5 Feb '26 |
Shareholding
Sas of Jun 202653.19%Promoter
Promoters53.19%0.02
FIIs17.35%0.17
DIIs21.59%0.22
Public7.48%0.40
Government0.01%
Ownership trend
Peers
P7 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Dr Lal Pathlabs | ₹1,759.20 | 52.45 | 29,491 | 0.80% | 171 | +28.02% | 798 | +19.10% | 28.00% |
| Vijaya Diagnost. | ₹1,313.90 | 78.23 | 13,533 | 0.15% | 48 | +34.56% | 219 | +26.63% | 21.29% |
| Metropolis Healt | ₹570.25 | 60.20 | 11,823 | 0.35% | 51 | +74.43% | 425 | +22.99% | 17.77% |
| Thyrocare Tech. | ₹564.25 | 49.69 | 8,981 | 1.65% | 51 | +34.06% | 240 | +24.34% | 35.38% |
| Nephrocare Health Services | ₹673.10 | 90.37 | 6,769 | 0.00% | 30 | +22.11% | 266 | +21.18% | 15.34% |
| Krsnaa Diagnost. | ₹544.80 | 17.21 | 1,767 | 0.50% | 43 | +105.89% | 173 | −0.93% | 12.70% |
| Suraksha Diagno. | ₹252.95 | 40.93 | 1,317 | 0.20% | 6 | −15.02% | 81 | +25.07% | 16.97% |
| Median: 14 Co. | ₹554.52 | 47.42 | 1,235 | 0.07% | 14 | +25.80% | 153 | +22.09% | 22.28% |
Filings
DAnnual reports11
Concall transcripts123
PPTJul 2026RECJul 2026TranscriptMay 2026PPTMay 2026RECMay 2026TranscriptFeb 2026PPTFeb 2026RECFeb 2026TranscriptNov 2025PPTNov 2025RECNov 2025TranscriptAug 2025PPTAug 2025TranscriptMay 2025PPTMay 2025RECMay 2025TranscriptFeb 2025PPTFeb 2025TranscriptOct 2024PPTOct 2024TranscriptAug 2024PPTAug 2024TranscriptMay 2024PPTMay 2024
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 8h - Q1 FY27 earnings conference call audio recording available on company website.Announcement under Regulation 30 (LODR)-Press Release / Media Release 13h - Q1 FY27 revenue rose 19.1% to Rs 798 Cr; PAT Rs 170 Cr; 50% interim dividend; two acquisitions.Announcement under Regulation 30 (LODR)-Investor Presentation 13hCorporate Action-Board approves Dividend 13h - Q1 FY27 results approved; INR 5 interim dividend, 119,300 options, and SHL/Neuome stake acquisitions.Announcement under Regulation 30 (LODR)-Acquisition 13h - Q1 FY27 results; Rs 5 interim dividend, record date July 30; 80% Ghana acquisition, 30% Neuome stake.